Cory Freedland

Nalo Therapeutics, Inc. is a company that focuses on developing therapeutics to address unmet needs in cancer. Nalo Therapeutics is based in Belmont, CA and the CEO of the company is Keith Wilson. The company targets oncogenic driver mutations and/or proteins that are often difficult to drug. The company was founded in 2017 and collaborates with UCSF scientific cofounders.

Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY.

Omniox, Inc. operates as a biopharmaceutical company which develops medicines for hypoxic diseases. Its technology overcomes fundamental biochemical shortcomings of hemoglobin-based and per fluorocarbon oxygen delivery approaches. The company was founded in 2006 by Stephen P. L. Cary, Michael A. Marletta, Jonathan Winger and Elizabeth Marshall Boon and is headquartered in San Carlos, CA.

Tentarix Biotherapeutics LP operates as a biotechnology company. The company is headquartered in La Jolla, CA.

Covid Apollo Project LLC aims to facilitate a safe and sustainable return to work and school by identifying, assembling, developing, and scaling the most promising COVID-19 diagnostic opportunities. Covid Apollo Project is based in Boston, MA. The private company was organized and funded under the leadership of RA Capital, a biotechnology-focused investment firm, in collaboration with Redmile Group, Samsara Biocapital, Perceptive Advisors, and Bain Capital. The CEO of the company is Stefan Willemsen.

Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.

Founded in 1958, Merrill Lynch Piece Fenner & Smith, Inc. is an SEC registered broker/dealer located in New York City. The firm is a subsidiary of BAC North America Holding Co. and their ultimate parent is Bank of America Corp. (NYSE BAC).

Orsobio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies to treat obesity and other severe metabolic disorders, such as type 2 diabetes, NASH, and severe dyslipidemias. The company is based in Palo Alto, CA. The company has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. Orsobio has a team of physicians and scientists who are dedicated to developing therapies to treat organ failure in patients with severe metabolic disorders. The company was founded by Mani Subramanian, who has been the CEO since incorporation.